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Surface chargeOne of the major limitations in gene therapy is an inability of naked siRNA to passively diffuse through neg-
atively charged cell membranes. Therefore, the siRNA transport into a cell requires efﬁcient carriers. In this
work we analyzed the charge-dependent interaction of the complexes of cationic carbosilane dendrimers
(CBD) and anti-HIV siRNA (dendriplexes) with the model membranes — large unilamellar vesicles (LUV).
We used the second generation of branched with CBD carbon–silicon bonds (CBD-CS) which are water-
stable and that of oxygen–silicon bonds (CBD-OS) which are slowly hydrolyzed in aqueous solutions. The
LUVs were composed of zwitterionic dimyristoylphosphatidylcholine (DMPC), negatively charged
dipalmitoylphosphatidylglycerol (DPPG) and their mixture (DMPC/DPPG, molar ratio 7:3). The interaction
of dendriplexes with LUVs affected both zeta potential and size of the vesicles. The changes of these values
were larger for the negatively charged LUV. CBD-CS resulted in the decrease of zeta potential values to
more negative ones, whereas an opposite effect took place for CBD-OS suggesting a different kind of interac-
tion between LUVs and the dendriplexes. The results indicate that both CBD-CS and CBD-OS can be used for
transport of siRNA into the cells. However, CBD-CS are preferred due to a better stability in water and
improved bioavailability of siRNA on their surface.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Strategies for inhibition of gene expression have been applied in
several therapeutic applications including the treatment of HIV infec-
tion [1–4]. For this purpose, siRNA should be transported through cell
membrane into the cytoplasm. However, the naked siRNA is unable to
passively diffuse through the negatively charged cell membranes.
There is also a tendency of antisense drugs to bind non-speciﬁcally
to the serum proteins due to electrostatic interactions [5]. These in-
teractions decrease a drug efﬁcacy. In order to obtain the desired
therapeutic effects higher doses of drug are necessary, which, howev-
er, can be toxic for organisms. The HIV virus contains in its genome
some genes which can be considered as a potential target for siRNA
[1]. Therefore, RNAi could be a promising therapeutic tool for HIV/
AIDS treatment. Every drug based on RNAi should be stable, selective,
non toxic and should easily penetrate through the cell membrane.arbosilane dendrimers; DMPC,
palmitoylphosphatidylglycerol;
48 426354474.
.
rights reserved.Thus, a substantial effort is required to develop a proper delivery
vehicle for siRNA in order to target viral mRNA inside the cell.
Dendrimers and lipid vesicles represent two of themost thoroughly
studied categories of nanoparticles that could be used as carriers of bio-
active molecules. With careful tailoring of their physicochemical char-
acteristics and thermodynamic parameters these nanocarriers can
alter the ADME proﬁle (Absorption, Distribution, Metabolism and Ex-
cretion) of a candidate molecule leading to more potent therapeutic
agents [6–11]. An attractive approach for delivery of siRNA to cells is
based on cationic dendrimers [12–17]. The cationic dendrimers can
form complexes with nucleic acids, and are widely studied as carriers
for the transfection of cells with DNA and siRNAs in vitro [18]. Cationic
dendrimers interact efﬁciently with nucleic acids, forming dendrimer/
nucleic acid complexes by bonding to the surface groups. Among the
cationic dendrimers the carbosilane dendrimers (CBD) are of special in-
terest. They have been synthesized speciﬁcally for siRNA and oligonu-
cleotide delivery system [19–21]. Interaction between dendrimers and
siRNA or oligonucleotide has electrostatic nature due to negative charge
of oligonucleotide backbone and positive charge of dendrimer function-
al groups. CBD are branched structures made of either carbon–silicon
bonds (CBD-CS) (Fig. 1A) which are stable in water or oxygen–silicon
bonds (CBD-OS) (Fig. 1B) which are slowly hydrolyzed in aqueous
Fig. 1. Molecular structure of the carbosilane dendrimers 2nd generation. With Si\C bonds — CBD-CS (BDBR0011); with Si\O bonds — CBD-OS (NN16).
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time-dependent release between 4 and 24 h [22]. CBD can form stable
complexeswith nucleic acids and protect them frombinding to proteins
[23]. For drug administration into the bloodstream it is also important
to protect DNA/RNA from sequestration and degradation [17,23]. Sec-
ond generation CBDs show good toxicity proﬁles in primary cell cul-
tures and erythrocytes up to concentrations of 5 μM [24]. There is also
some evidence on antibacterial properties of CBD. The activity of CBD
depends on the dendrimer generation and on the type of bacteria.
First and second generation dendrimers show the most efﬁcient
antibacterial properties [25]. In this work we used a second generation
of CBD-CS and CBD-OS as carriers for anti-HIV siRNA (siGAG1) and
studied the interaction of these dendriplexes with vesicles composed
of zwitterionic or negatively charged phospholipids. The aim of the pre-
sent work was to investigate, by means of zeta potential, size and ﬂuo-
rescence anisotropy methods, the interaction of the dendriplexes with
vesicles that mimic the cell surface.2. Materials and methods
2.1. Materials
CBDs were synthesized in the Departamento de Quimica Inorganica,
Universidad de Alcala, Spain as described elsewhere [22,24,26]. The struc-
ture of CBD-CS: C128H316I16N16O8Si13+16 (Mw=4603.56 g/mol) and CBD–
OS: C144H348I16N16Si13+16 (Mw=4 699.99 g/mol) are presented in Fig. 1A
and B, respectively. siRNA: 3′-UGUCACUUCCCCUUGGUUCUCTT-5′, was
purchased from Sigma-Aldrich (USA).
Phospholipids: 1,2-dimyristoyl-sn-glycero-3-phosphocholine
(DMPC), dipalmitoylphosphatidylglycerol (DPPG) were purchased
from Avanti Polar Lipids Inc (USA). All other reagents used were of
analytical grade and purchased from Sigma-Aldrich.2.2. Formation of siRNA-dendriplexes
Dendriplexes were formed by addition of dendrimers into siRNA so-
lutions at a 4:1 (dendrimer/siRNA) molar ratio. The mixture was
vortexed and incubated for 10 min at room temperature (approx.
20 °C). The resulting siRNA/dendrimer complex used in experiments
contained 0.5 μM siRNA with siRNA:dendrimer ratio of 1:4 (mol/mol)
(see also [15] for method description).2.3. Liposome preparation
Large unilamellar vesicles (LUV), composed either of DMPC or
DMPC/DPPG in a molar ratio 7:3 or DPPG, were prepared using extru-
sion method [27]. Brieﬂy, an appropriate amount of lipid solutions in
chloroform was placed in a round bottom ﬂask and the thin lipid ﬁlm
was formed by a slow removal of the solvent under argon atmo-
sphere. Remaining solvent traces were removed under vacuum
using a rotary evaporator over a water bath at 37 °C for 30 min. The
resulting lipid ﬁlm on the wall of the ﬂask was hydrated with an ap-
propriate volume of buffer resulting in a ﬁnal lipid concentration of
5 mg/ml. The mixture was vortexed with glass beads for 5 min,
allowed to equilibrate under argon atmosphere at 37 °C (above the
gel-liquid crystal transition temperature of the lipid mixture) for
30 min. Subsequently the liposome suspension was forced to pass at
least 15 times through a polycarbonate membrane of 100 nm porosi-
ty (Nuclepore, T–E), mounted in a mini-extruder (Avanti Polar Lipids)
ﬁtted with two 1 ml Hamilton gastight syringes. Exposure to light
was minimized throughout the liposome preparation process
[27–29].
2.4. Measurement of vesicle size
The particles size and size distribution (z-average mean) were mea-
sured using dynamic light scattering (DLS) in a photon correlation spec-
trometer (Zetasizer Nano-ZS, Malvern Instruments, UK) [30]. The
refraction factor was assumed 1.33 while the detection angle was 90°
and the wavelength was 633 nm. Samples in 10 mM PBS, pH 7.4 were
placed in the plastic cells DTS0012 (Malvern) and measured at 25 °C.
The data were analyzed using the Malvern software.
2.5. Measurement of zeta potential
The particle charge measurements were conducted using a
phase analysis light scattering with Zetasizer Nano-ZS. The electro-
phoretic mobility of the dynamic light scattering samples in an ap-
plied electric ﬁeld was measured in Malvern capillary plastic cells
(DTS1061). Samples were prepared and measured at 25 °C in
10 mM PBS, pH 7.4 (PBS was ﬁltered through 22 nm ﬁlter paper
prior to use). Nine zeta potential measurements were collected for
each dispersion, and the results were averaged. The zeta potential
value was calculated directly from the Helmholtz-Smoluchowski
equation using the Malvern software [31].
Fig. 2. The changes of particle size— A; zeta potential— B; ﬂuorescence polarization— C, of
siRNAupon addition of CBD-CS— (□) or CBD-OS— (◊). Dendrimer/siRNAmolar ratioswere:
0.5:1; 1:1; 2:1; 3:1; 4:1; 5:1; 6:1; 8:1; 12:1; and 14:1. 10 mM PBS, pH 7.4, 25 °C. n=3.
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Samples were prepared by incubation of 0.1 μM siRNA labeled
with ﬂuorescein with various concentrations of CBDs in 10 mM PBS,
pH 7.4 at room temperature (approx. 20 °C), and the changes in ﬂuo-
rescence polarization were measured using a Perkin Elmer LS-50B
spectroﬂuorimeter (UK) at 25 °C. Polarization was monitored at
521 nm (with a bandwidth of 3 nm) with excitation at 494 nm
(with a bandwidth of 5 nm). Polarization is expressed as:
P ¼ IV−GIH
IV þ GIH
where IV and IH are the vertically and horizontally polarized emission
intensities, respectively, when vertically polarized light is used to
excite the sample. The G factor (measured experimentally) takes
into account instrumental effects and can be expressed as:
G ¼ IHV
IHHwhere IHV and IHH are the vertically and horizontally polarized emis-
sion intensities, respectively, when horizontally polarized light is
used to excite the sample. The polarization of each sample was calcu-
lated from an average of 6 measurements of IV and IH, and four values
of such a set of averages were collected [32].
2.7. Statistical analysis
Statistical analysis and exponential curve ﬁtting were performed
using Origin 8 (Microcal Software Inc., Northampton, MA) software.
Results are expressed as means±standard deviation (SD).
3. Results
3.1. Interaction between siRNA and dendrimers
In order to estimate the efﬁciency of the siRNA–dendrimers interac-
tion we characterized these complexes by DLS and zeta potential
methods. Samples for the light scattering measurements were prepared
as mentioned above. The addition of dendrimers to siRNA in a range of
(0.5–16):1 molar ratio led to a signiﬁcant increase in zeta potential in
comparison with the respective controls: from −40.17±2.13 to 6.0±
1.79 mV and from −27.44±3.16 to 7.8±2.19 mV, for CBD-CS and
CBD-OS respectively. The zeta potential curves reached a plateau at den-
drimer/siRNA molar ratios of (4.5–5):1 and (3.5–4):1, respectively
(Fig. 2B).
Particle size analysis by DLS indicated the formation of complexes
between the dendrimers and siRNA. Upon addition of the dendrimers,
the particle size increased from ~200 to ~700 nm and the size of thus
formed dendriplexes was stable from the dendrimer/siRNA molar
ratio of 5:1 for CBD-OS and 6:1 for CBD-CS (Fig. 2A). Further increase
of dendrimer concentration did not change the dendriplex size. These
data lead to the conclusion that at the CBD/siRNA (4–6):1 molar ratio
the dendriplexes were fully saturated with dendrimers.
To conﬁrm the formation of dendrimer/siRNA complexes, as it was
suggested by DLS and zeta potential results, we also carried out ﬂuo-
rescence polarization measurements. Fluorescence polarization (P) of
the ﬂuorescein-labeled siRNA in the presence and absence of the den-
drimers is shown in Fig. 2C. The increase in the P values suggests a
decrease in mobility of the probe molecules (that are bound to one
of the strands of siRNA) as a result of the attaching of siRNAmolecules
to the dendrimers. From the data presented in Fig. 2C, it can be seen
that in the presence of gradually increasing concentrations of CBD-
CS and CBD-OS, the P values signiﬁcantly increased 3.88 and 2.65
times, respectively.
3.2. Interactions between dendrimers and vesicles
LUVs of a different lipid composition: (a) DMPC; (b) DMPC/DPPG
(molar ratio 7:3); and (c) DPPG were used in order to model the inter-
action of CBDs with cell membrane. Changes in the average size of the
vesicles in the presence of various concentrations of either CBD-CS or
CBD-OS dendrimers are shown in Fig. 3 (top panels). For LUVs com-
posed of DMPC only a slight increase in the vesicle mean diameter
was observed when dendrimers were present in the suspension. How-
ever, the diameter of LUVs practically did not depend on the presence of
dendrimers at rather high concentrations. For the vesicles formed with
DMPC/DPPG the difference in the mean diameter of dendrimer-treated
and untreated vesicles were larger and statistically signiﬁcant for CBD-
CS, but not for CBD-OS. For the vesicles prepared from pure DPPG the
average size increased dramatically already at low dendrimer
concentrations.
The effect of dendrimers on zeta potential of DMPC, DMPC/DPPG
(molar ratio 7:3) or DPPG LUVs is presented in Fig. 3 (bottom panels).
The zeta potentials of the DMPC vesicles varied from −0.98 mV to
−6.4 mV and of the DPPG vesicles from−13.58 mV to−20.35 mV. It
Fig. 3. Average size and zeta potential of the vesicles composed of: (◊)—DMPC; (□)—DMPC/DPPG (molar ratio 7:3); and (Δ)—DPPG, upon addition of CBD-CS or CBD-OS dendrimers in
increased concentrations. The concentration of vesicles was 50 μM. Lipids/dendrimers molar ratios were: 200:1; 100:1; 50:1; 33:1; 25:1; 10:1; 5:1; and 2:1. 10 mM PBS, pH 7.4, 25 °C.
n=3.
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itive values took place already at low dendrimer concentrations.
3.3. Interaction of dendrimer/siRNA complexes with vesicles
The interaction between dendrimer/siRNA complexes (dendriplexes)
and vesicles of different lipid compositionwas studied by adding aliquots
of the dendriplexes to the vesicle solutions in increasing dendriplex/lipid
ratios and monitoring the changes in particles size and zeta potential.
Dendriplexes used in these experiments were formed by adding den-
drimers to siRNA solutions at a 4:1 molar ratio and incubating theFig. 4. Variation of vesicles zeta potential values following interactionwith siRNA/CBD-CS or siR
(molar ratio 7:3); and (Δ) — DPPG. The lipid concentration was 10 μM. For dendriplexes forma
ratios were: 100:1, 50:1, 20:1, 14:1, and 10:1. 10 mM PBS, pH 7.4, 25 °C. n=3.mixture for 10 min. The LUVs of the following lipid composition were
tested: (a) DMPC; (b) DMPC/DPPG (molar ratio 7:3); and (c) DPPG.
The results shown in Fig. 4 indicate that addition of the
dendriplexes based on CBD-OS (right panel) increased zeta potential
values of all vesicle suspensions. This effect is similar to that observed
for dendrimer–vesicle interactions (i.e. in the absence of siRNA) (see
Fig. 3, bottom panels). Likely, the siRNA/CBD-OS dendriplexes formed
complexes with vesicles and the extent of the complexation
depended on the liposome charge and dendriplex concentration.
For DMPC the presence of dendriplexes changed the zeta potential
from−17.8±2.24 to 10.85±0.17 mV. The positive value was reachedNA/CBD-OS dendriplexes. The vesicle lipid composition: (◊)—DMPC; (□)—DMPC/DPPG
tion siRNA/dendrimer molar ratio — 1:4 was used. Lipids/dendriplexes (by siRNA) molar
Fig. 5. Variation in vesicle zeta average size values following interaction with siRNA/CBD-CS or siRNA/CBD-OS dendriplexes. Vesicles were of the following composition: A— DMPC;
B — DMPC/DPPG (molar ratio 7:3); and C — DPPG. Size of the circles stands for percentage (by volume) of total sum of the particles. (●) — high size peak; (○) — low size peak. The
lipid concentration was 10 μM. For dendriplexes formation siRNA/dendrimer molar ratio — 1:4 was used. Lipids/dendriplexes molar ratios were: 100:1, 50:1, 20:1, 14:1, and 10:1.
10 mM PBS, pH 7.4, 25 °C. n=3.
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DPPG mixture the zeta potential curves reached positive values for the
dendriplex concentration of 0.7 μM where the zeta potential was chan-
ged from −21.5±4.43 to 6.35±0.63 mV (DMPC/DPPG) and from
−20.4±2.7 to 6.85±0.77 mV (DPPG). In contrast the increased con-
centrations of dendriplex formed using CBD-CS dendrimer resulted
the gradual decreases in the initial LUVs zeta potential (Fig. 4, left
panel). In the presence of 1 μM CBD-CS-based dendriplexes, the
zeta potential decreased from −13.87±4.37 to −30.4±4.24 mV
(DMPC); from −15.06±0.92 to −34.83±2.64 mV (DMPC/DPPG)
and from−14.14±5.43 to−29.38±1.16 mV (DPPG).
The zeta size of the vesicles upon addition of dendriplexes is pres-
ented in Fig. 5. Obviously, the presence of dendriplexes in a sample
resulted in a decrease in the proportion of particles with a size of~100 nm, which was found for unmodiﬁed vesicles. With increasing
dendriplexes concentration a larger number of vesicles could form
complexes with dendriplexes. This caused an increase in the percent-
age of the particles sized above 700 nm, thus reducing the amount of
particles with size of 100 nm. The increase in the dendriplex size also
suggests that the dendriplex–vesicle complexes might form aggre-
gates with a size from 800 to 1000 nm (Fig. 5).
4. Discussion
Shcharbin et al. [15] demonstrated that carbosilane dendrimerswere
able to form complexes with siRNA. We suggest that siRNA attached to
the dendrimers should be protected fromRNAse degradation and the ef-
ﬁciency of siRNA/dendrimer complexes bioavailability may depend on
Fig. 6. Schematic drawing of the possible interaction of dendriplexes, siRNA/CBD-CS and siRNA/CBD-OS, with a model cell.
2214 M. Ionov et al. / Biochimica et Biophysica Acta 1818 (2012) 2209–2216the siRNA:dendrimers ratio. In order to evaluate the character of the
siRNA–dendrimers interaction we monitored these complexes using
DLS and zeta potential methods. These measurements indicated that
the formed particles exhibited a uniform potential distribution at zeta
potential values above zero. Analysis of particle size indicated the forma-
tion of complexes (~600–700 nm) at dendrimer/siRNA molar ratio of
(4–6):1. Considering that the characteristic dimensions of dendrimers
are of approximately 2 nm, it is conceivable that the aggregates are
formed in the presence of siRNA. The increasing zeta potential and size
for the CBD/siRNA complexes indicate a signiﬁcant change in the surface
and size properties of the dendriplexes. The results obtained using ﬂuo-
rescence polarization method conﬁrm the conclusions from DLS and
zeta potential studies that siRNA molecules interacted with dendrimers
and formed stable complexes in a molar ratio range (4–6):1.
In order to model the interaction of CBD dendrimers with cell mem-
branes we used LUVs of a different composition: (a) DMPC; (b) DMPC/
DPPG (molar ratio 7:3); and (c) DPPG. The used lipid compositions
allowed for varying the surface charge of the LUVs, which plays an im-
portant role in the interaction of cationic dendrimers with lipid bilayers.
For LUVs composed of DMPC the presence of dendrimers did not signif-
icantly affect the vesicle mean diameter. DMPC is a zwitterionic lipid
that, at physiological pH, formsmembranes with practically zero surface
charge density. This is also evident from zeta potential measurements
for DMPC-LUVs which is close to zero (Fig. 3, bottom panel). Thus,
obtained results suggest rather weak interactions of dendrimers with
neutral DMPC. The difference in the mean diameter of dendrimer-
treated and untreated DMPC/DPPG vesicles was more pronounced
than in case of vesicles composed of DMPC. For the vesicles prepared
from pure DPPG the average size increased dramatically even at low
concentration of dendrimers. This suggests that the dendrimer–vesicle
complexes formed aggregates, and that CBD-CS and CBD-OS interacted
strongly with the negatively-charged lipid bilayers. As expected, the
lipid composition plays an important role in the membrane–dendrimer
interactions, however, it seems to be accomplished by different ways:
without affecting the vesicle size (neutral vesicles) or by formation of
relatively large aggregates (negatively charged vesicles). The signiﬁcant
increase in the mean diameter of the DMPC/DPPG vesicles from their
original values suggests that the dendrimer-treated vesicles aggregat-
ed. Since aggregation may be used as a measure of the vesicle physical
stability, we can conclude that the interaction of CBD-CS and CBD-OS
with negatively charged LUVs bilayers modiﬁed their physical stability.
On the other hand, the vesicle mean size practically did not change
(CBD-OS) or only slightly increased (CBD-CS) when the DMPC/DPPG
vesicles were used (Fig. 3). Thus, differences in surface charge of LUVsdid underlie the mode of liposome/dendrimer interactions. Cationic
dendrimers bound stronger to LUVs containing negatively charged
lipids.
Zeta potential results show the rise of zeta potential to the positive
values for all studied LUVs formulations in the presence of dendrimers.
After the initial sharp increase, the saturation took place for dendrimer
concentrations higher than 10 μM for CBD-CS and 5 μM for CBD-OS,
suggesting slightly stronger charge neutralization of the liposome sur-
face by CBD-OS dendrimers in comparison with CBD-CS. Nevertheless,
the ﬁnal value of potential change caused by both dendrimers in the sat-
uration regionwas not statistically signiﬁcant. The interaction of dendri-
mers with the liposome surface was rather strong and their ability to
change zeta potential in the saturation region practically did not depend
on the liposome zeta potential, i.e. on the surface charge. However, for
negatively charged vesicles, the dendrimer concentration at which the
surface charge polarity changes from negative to positive values, was
shifted to the higher dendrimer concentrations (Fig. 3). This suggests
an electrostatic nature of the dendrimer–vesicle interactions. The plot
of zeta potential vs. dendrimer concentration has the shape of the Lang-
muir isotherm. Thus, it is conceivable that the dendrimers do not interact
upon the binding to the liposome surface.
The interaction between dendrimer/siRNA complexes (dendriplexes)
and vesicles of different lipid composition (DMPC, DMPC/DPPG (molar
ratio 7:3) and DPPG) was studied by monitoring the changes in zeta po-
tential and particles size. For DMPC vesicles the presence of CBD-OS/
siRNA dendriplexes signiﬁcantly increased the zeta potential from nega-
tive to positive values. One should, however, note that the experiments
were performed at rather low concentration of DMPC (10 μM), which
was not enough to provide sufﬁcient sensitivity for zeta potential detec-
tion. Therefore, the negative value of this potential does not reﬂect the
surface properties of pure DMPC vesicles. At a sufﬁciently high vesicle
concentration (50–100 μM) the zeta potential was equal approximately
−1.5 mV, which reﬂects the zwitterionic nature of DMPC. However, for
the higher vesicle concentration it was impossible to provide desired
concentration of dendriplexes due to their low solubility.
For negatively charged DPPG and DMPC/DPPG vesicles the zeta
potential in the presence of CBD-OS/siRNA dendriplexes was also dra-
matically increased.
In contrast to the above results, the changes of zeta potential for
siRNA/CBD-CS dendriplexes were in the opposite direction. In the
presence of CBD-CS/siRNA dendriplexes the initial LUVs zeta potential
gradually decreased. Considering a different nature of dendrimers
used for complexation with the siRNA, we have proposed a scheme
depicting differences in the liposome–dendriplexes interaction
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of CBD-CS dendriplexes can be explained by the negatively charged
siRNA, attached to the liposome surface via molecular self‐assembly
of dendrimers acting as a linker. In contrast, the increased zeta poten-
tial of the vesicles in the presence of CBD-OS dendriplexes could be a
consequence of the presence of positively charged dendrimers loca-
ted on the surface of siRNA layer (Fig. 6).
The zeta size of the vesicles upon addition of dendriplexes was sig-
niﬁcantly increased. This fact also suggests that the dendriplex–vesicle
complexes might form aggregates with a size ~900 nm (Fig. 5). It
should be noted that a particle size serves not only as a parameter char-
acterizing the colloidal-drug-delivery system but also as a measure of
the system stability. Certainly, the aggregation and fusion of vesicles
would normally result in an increase in the particle size. In our experi-
ments, themost efﬁcient interaction between dendriplexes and vesicles
was found for the vesicles composed of DPPG. Thus, the surface charge
plays a key role in the dendriplex–liposome interactions. Analyzing the
obtained results we suggest that CBD-CS is a better candidate for siRNA
delivery to target cells than it is CBD-OS. Our statement is based on the
following reasons: 1. CBD-CS dendrimers aremore stable inwater solu-
tions, and 2. these dendrimers provide better bioavailability of siRNA as
anticipated from the scheme in Fig. 6.
5. Conclusion
In this work the effect of siRNA-carbosilane dendrimers complexes
on the size and zeta potential of the large unilamellar vesicles (LUVs)
of various lipid compositions was studied. Two types of dendrimers
were used, the core of which was either branches of carbon–silicon
bonds (CBD-CS) or oxygen–silicon bonds (CBD-OS). Both dendrimers
are terminated by amino groups, so they represent cationic particles
that are suitable for binding of the negatively charged siRNA. We
were interested in how the dendrimers alone aswell as their complexes
with siRNA would interact with neutral and negatively charged LUVs.
For this purpose we used vesicles composed of DMPC that form neutral
lipid bilayers, DPPG, that forms negatively chargedmembranes, and the
mixture of DMPC/DPPG (molar ratio 7:3) forming vesicleswith amode-
rately negatively charged surface. We have shown that both types of
dendriplexes, siRNA/CBD-CS and siRNA/CBD-OS (molar ratio 1:4), in-
teract with LUVs and cause a formation of large aggregates of about
800–1000 nm in diameter. The zeta potential of the LUVs was also
changed when dendriplexes were present and this effect depended
on the type of studied dendrimers. The vesicles surface charge plays
an important role in LUV–dendriplex interaction. The dendriplexes
interacted more strongly with the negatively charged LUV.
Based on the obtained results, we propose that the carbosilane den-
drimers can be considered for delivering siRNA into the target cells.
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